# Alethio Therapeutics

> Oxford biotechnology company developing targeted treatments for myeloproliferative neoplasms.

## Why it is interesting

Announced $90M Series A co-led by Sofinnova Partners and RA Capital on November 5, 2026; ATX-011 targets G6B in essential thrombocythaemia.

## Profile

- **Latest funding:** Series A — $90M (November 5, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $90M
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-06
- **Latest funding investors:** Sofinnova Partners, RA Capital Management, Oxford Science Enterprises

## Funding history

- Series A · $90M · November 5, 2026
  Source: https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 6, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/alethio-therapeutics